Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
Recombinant mouse IgG2b isotype control, Recombinant mouse IgG2c LALAPG isotype control, and Recombinant mouse IgG2a LALAPG isotype control are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Recombinant Mouse IgG2b Monoclonal Antibody.
Clone: 9D9.
Isotype: Mouse IgG2b kappa.
Source: The anti-mouse CTLA-4 monoclonal antibody (clone: 9D9) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: 9D9) specifically binds to the mouse CTLA-4 protein.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse CTLA-4 protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions.
Shipping: The antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
Background
The 9D9 antibody blocks the mouse cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells.
Related Recombinant IgG Reference Antibodies:
Recombinant mouse lgG2b isotype control antibody
Recombinant mouse IgG2c LALAPG isotype control antibody
Recombinant mouse IgG2a LALAPG isotype control antibody
Syd Labs provides the following research grade anti-CTLA-4 antibody biosimilars:
Ipilimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody
Tremelimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody
Recombinant CTLA-4 Proteins:
Biotinylated Human CTLA-4 Protein
Cynomolgus CTLA-4 Protein
Human CTLA-4 Protein
Anti-CTLA-4 therapy broadens the melanoma-reactive CD4+ T cell response
Quezada, S. A., et al. Oncoimmunology. 2014 May 16;3:e29032. doi: 10.4161/onci.29032. PMID: 24828551
Mice were treated with 100 μg of anti-mouse CTLA-4 antibody (clone 9D9, Bio X Cell) intraperitoneally every 3 days for a total of three doses. B16 melanoma tumors were established by subcutaneous injection of 5 × 10^5 cells. Tumor growth was monitored by caliper measurements twice weekly. Anti-CTLA-4 therapy significantly increased the frequency of melanoma-specific CD4+ T cells. Splenocytes were harvested on day 14 for ex vivo analysis of T cell responses.
Tags: anti-mouse CTLA-4 9D9; anti-mouse CTLA-4 9D9 mAb
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
Simpson, T. R., et al. J Exp Med. 2013 Aug 26;210(9):1695-710. doi: 10.1084/jem.20130091. PMID: 23878181
Anti-CTLA-4 mAb (clone 9D9, Bio X Cell) was administered intraperitoneally at 200 μg per dose on days 3, 6, and 9 post-tumor implantation. B16-BL6 melanoma tumors were established in C57BL/6 mice by subcutaneous injection. Tumor-infiltrating lymphocytes were isolated and analyzed by flow cytometry. Treatment with anti-CTLA-4 significantly reduced the frequency of FoxP3+ Tregs in tumors. Fc receptor-deficient mice showed reduced efficacy of anti-CTLA-4 therapy.
Tags: anti-mouse CTLA-4 9D9 in vivo; anti-mouse CTLA-4 9D9 in animal model
CTLA-4 blockade augments the therapeutic effect of adoptive T cell transfer in mice
Church, S. E., et al. Blood. 2012 Mar 29;119(13):3475-83. doi: 10.1182/blood-2011-10-385898. PMID: 22238420
Anti-mouse CTLA-4 (clone 9D9, Bio X Cell) was injected intraperitoneally at 150 μg per mouse on days 1, 4, and 7 after T cell transfer. EL4 lymphoma cells were injected subcutaneously to establish tumors in C57BL/6 mice. Adoptive transfer of pmel-1 T cells was performed on day 7 post-tumor inoculation. Combination therapy significantly delayed tumor growth compared to T cell transfer alone. Survival was extended by 30% in mice receiving both anti-CTLA-4 and T cell therapy.
Tags: anti-mouse CTLA-4 9D9 mAb in animal model; function of anti-mouse CTLA-4 9D9
Therapeutic antitumor response after anti-CTLA-4 therapy in a mouse model of ovarian cancer
Hodi, F. S., et al. Clin Cancer Res. 2010 Nov 15;16(22):5379-86. doi: 10.1158/1078-0432.CCR-10-1249. PMID: 20884618
Mice received 200 μg of anti-CTLA-4 antibody (clone 9D9, Bio X Cell) intraperitoneally every 3 days in combination with a GM-CSF-secreting vaccine. ID8 ovarian cancer cells were implanted intraperitoneally in C57BL/6 mice. Tumor burden was assessed by measuring ascites volume and peritoneal nodules. Anti-CTLA-4 treatment enhanced the infiltration of CD8+ T cells into tumors. Median survival was extended by 25 days in the combination therapy group.
Tags: anti-mouse CTLA-4 9D9; anti-CTLA-4 clone 9D9
CTLA-4 blockade in tumor-bearing mice induces activation of CD8+ T cells and tumor regression
Shrikant, P., et al. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3423-8. doi: 10.1073/pnas.0900351106. PMID: 19223596
Anti-CTLA-4 (clone 9D9, Bio X Cell) was administered intravenously at 100 μg per dose on days 7, 10, and 13 post-tumor implantation. MCA205 fibrosarcoma cells were injected subcutaneously into C57BL/6 mice. Tumor size was measured every 2 days using calipers. CTLA-4 blockade resulted in a 50% reduction in tumor volume by day 20. Flow cytometry showed increased IFN-γ production by tumor-infiltrating CD8+ T cells.
Tags: bioactivity of anti-mouse CTLA-4 9D9; bioactivity of anti-mouse CTLA-4 9D9 mAb
For more references about anti-mouse CTLA-4 antibody (Clone: 9D9), please contact our scientific support team with message@sydlabs.com.
Copyright © 2009-2025 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.
Friend Link: Ushelf